BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 33513125)

  • 1. Cardiometabolic and psychological effects of dual-release hydrocortisone: a cross-over study.
    Dineen R; Martin-Grace J; Ahmed KMS; Frizelle I; Gunness A; Garrahy A; Hannon AM; O'Reilly MW; Smith D; McDermott J; Healy ML; Agha A; Pazderska A; Gibney J; Thompson CJ; Behan LA; Sherlock M
    Eur J Endocrinol; 2021 Feb; 184(2):253-265. PubMed ID: 33513125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching From Immediate-Release to Fractionated Dual-Release Hydrocortisone May Improve Metabolic Control and QoL in Selected Primary Adrenal Insufficiency Patients.
    Delle Cese F; Corsello A; Cintoni M; Locantore P; Pontecorvi A; Corsello SM; Paragliola RM
    Front Endocrinol (Lausanne); 2020; 11():610904. PubMed ID: 33597926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Achieving a physiological cortisol profile with once-daily dual-release hydrocortisone: a pharmacokinetic study.
    Johannsson G; Lennernäs H; Marelli C; Rockich K; Skrtic S
    Eur J Endocrinol; 2016 Jul; 175(1):85-93. PubMed ID: 27129362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What factors have impact on glucocorticoid replacement in adrenal insufficiency: a real-life study.
    Puglisi S; Rossini A; Tabaro I; Cannavò S; Ferrau' F; Ragonese M; Borretta G; Pellegrino M; Dughera F; Parisi A; Latina A; Pia A; Terzolo M; Reimondo G
    J Endocrinol Invest; 2021 Apr; 44(4):865-872. PubMed ID: 32779106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue Glucocorticoid Metabolism in Adrenal Insufficiency: A Prospective Study of Dual-release Hydrocortisone Therapy.
    Dineen RA; Martin-Grace J; Ahmed KMS; Taylor AE; Shaheen F; Schiffer L; Gilligan LC; Lavery GG; Frizelle I; Gunness A; Garrahy A; Hannon AM; Methlie P; Eystein SH; Stewart PM; Tomlinson JW; Hawley JM; Keevil BG; O'Reilly MW; Smith D; McDermott J; Healy ML; Agha A; Pazderska A; Gibney J; Behan LA; Thompson CJ; Arlt W; Sherlock M
    J Clin Endocrinol Metab; 2023 Nov; 108(12):3178-3189. PubMed ID: 37339332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-release hydrocortisone and its benefits on cognitive function and quality of sleep.
    Krekeler C; Kropp P; Blacha AK; Rahvar AH; Harbeck B
    Endocrine; 2021 Apr; 72(1):223-233. PubMed ID: 33625720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency.
    Nilsson AG; Marelli C; Fitts D; Bergthorsdottir R; Burman P; Dahlqvist P; Ekman B; Engström BE; Olsson T; Ragnarsson O; Ryberg M; Wahlberg J; Lennernäs H; Skrtic S; Johannsson G
    Eur J Endocrinol; 2014 Sep; 171(3):369-77. PubMed ID: 24944332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GLUCOCORTICOID REPLACEMENT REGIMENS IN CHRONIC ADRENAL INSUFFICIENCY: A SYSTEMATIC REVIEW AND META-ANALYSIS.
    Al Nofal A; Bancos I; Benkhadra K; Ospina NM; Javed A; Kapoor E; Muthusamy K; Brito JP; Turcu AF; Wang Z; Prokop L; Erickson DZ; Lteif AN; Natt N; Murad MH
    Endocr Pract; 2017 Jan; 23(1):17-31. PubMed ID: 27631672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study.
    Nilsson AG; Bergthorsdottir R; Burman P; Dahlqvist P; Ekman B; Engström BE; Ragnarsson O; Skrtic S; Wahlberg J; Achenbach H; Uddin S; Marelli C; Johannsson G
    Eur J Endocrinol; 2017 Jun; 176(6):715-725. PubMed ID: 28292927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency.
    Mah PM; Jenkins RC; Rostami-Hodjegan A; Newell-Price J; Doane A; Ibbotson V; Tucker GT; Ross RJ
    Clin Endocrinol (Oxf); 2004 Sep; 61(3):367-75. PubMed ID: 15355454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency.
    Quinkler M; Miodini Nilsen R; Zopf K; Ventz M; Øksnes M
    Eur J Endocrinol; 2015 May; 172(5):619-26. PubMed ID: 25656494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency.
    Bleicken B; Hahner S; Loeffler M; Ventz M; Decker O; Allolio B; Quinkler M
    Clin Endocrinol (Oxf); 2010 Mar; 72(3):297-304. PubMed ID: 19508599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An observational study on adrenal insufficiency in a French tertiary centre: Real life versus theory.
    Castinetti F; Sahnoun M; Albarel F; Morange I; Philippon M; Conte-Devolx B; Brue T
    Ann Endocrinol (Paris); 2015 Feb; 76(1):1-8. PubMed ID: 25617904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Modified-release hydrocortisone for glucocorticoid deficiency].
    Nowotny H; Reisch N
    Internist (Berl); 2020 Jun; 61(6):565-572. PubMed ID: 32394073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved Urinary Cortisol Metabolome in Addison Disease: A Prospective Trial of Dual-Release Hydrocortisone.
    Espiard S; McQueen J; Sherlock M; Ragnarsson O; Bergthorsdottir R; Burman P; Dahlqvist P; Ekman B; Engström BE; Skrtic S; Wahlberg J; Stewart PM; Johannsson G
    J Clin Endocrinol Metab; 2021 Mar; 106(3):814-825. PubMed ID: 33236103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of Time-Point Serum Cortisol and ACTH Measurements for the Adjustment of Glucocorticoid Replacement in Adrenal Insufficiency.
    Rousseau E; Joubert M; Trzepla G; Parienti JJ; Freret T; Vanthygem MC; Desailloud R; Lefebvre H; Coquerel A; Reznik Y;
    PLoS One; 2015; 10(8):e0135975. PubMed ID: 26317782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial.
    Isidori AM; Venneri MA; Graziadio C; Simeoli C; Fiore D; Hasenmajer V; Sbardella E; Gianfrilli D; Pozza C; Pasqualetti P; Morrone S; Santoni A; Naro F; Colao A; Pivonello R; Lenzi A
    Lancet Diabetes Endocrinol; 2018 Mar; 6(3):173-185. PubMed ID: 29229498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatosensory function in patients with secondary adrenal insufficiency treated with two different doses of hydrocortisone-Results from a randomized controlled trial.
    Werumeus Buning J; Konopka KH; Brummelman P; Koerts J; Dullaart RPF; van den Berg G; van der Klauw MM; Tucha O; Wolffenbuttel BHR; van Beek AP
    PLoS One; 2017; 12(7):e0180326. PubMed ID: 28686664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation.
    Johannsson G; Nilsson AG; Bergthorsdottir R; Burman P; Dahlqvist P; Ekman B; Engström BE; Olsson T; Ragnarsson O; Ryberg M; Wahlberg J; Biller BM; Monson JP; Stewart PM; Lennernäs H; Skrtic S
    J Clin Endocrinol Metab; 2012 Feb; 97(2):473-81. PubMed ID: 22112807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the Impact of Short- and Long-Term Hydrocortisone Replacement on Cognitive Function, Quality of Life and Catecholamine Secretion: A Pilot Study.
    Harbeck B; Danneberg S; Rahvar AH; Haas CS; Lehnert H; Kropp P; Mönig H
    Appl Psychophysiol Biofeedback; 2016 Sep; 41(3):341-7. PubMed ID: 27170300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.